Tango Therapeutics, Inc.
TNGX
Kedudukan dalam Saham
#4546
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and... Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
Harga Saham
$27.18
Disegerakkan terakhir: 2026-07-31
Modal Pasaran
$3.38B
Perubahan (1 hari)
-1.41%
Perubahan (1 tahun)
202.34%
Negara
US
Perdagangan Tango Therapeutics, Inc. (TNGX)
Kategori
Healthcare
Sejarah pecahan saham untuk Tango Therapeutics, Inc. (TNGX)
Saham Tango Therapeutics, Inc. (simbol: TNGX) telah mengalami sejumlah 0 pecahan saham.
Pecahan saham terkini berlaku pada Oct 21, 2026.
Satu saham TNGX yang dibeli sebelum Oct 21, 2026 kini bersamaan dengan 0 saham TNGX.
Pecahan saham terkini berlaku pada Oct 21, 2026.
Satu saham TNGX yang dibeli sebelum Oct 21, 2026 kini bersamaan dengan 0 saham TNGX.
Senarai pecahan saham
| Tahun | Pecahan | Gandaan | Gandaan Kumulatif |
|---|---|---|---|
| Tidak cukup data untuk tarikh yang disediakan. | |||
Pecahan saham untuk syarikat pesaing atau serupa
| Syarikat | Bilangan pecahan saham | Gandaan Kumulatif | Negara |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
